119-hr1922

[Congressional Bills 119th Congress]
[From the U.S. Government Publishing Office]
[H.R. 1922 Introduced in House

    (IH) ]

<DOC>

119th CONGRESS
 1st Session
 H. R. 1922

To amend title XVIII of the Social Security Act to exempt certain drugs 
 from the part D manufacturer discount program under the Medicare 
 program.

_______________________________________________________________________

 IN THE HOUSE OF REPRESENTATIVES

 March 6, 2025

 Mr. Garbarino (for himself, Mrs. Harshbarger, and Mr. Suozzi) 
 introduced the following bill; which was referred to the Committee on 
 Energy and Commerce, and in addition to the Committee on Ways and 
 Means, for a period to be subsequently determined by the Speaker, in 
 each case for consideration of such provisions as fall within the 
 jurisdiction of the committee concerned

_______________________________________________________________________

 A BILL

To amend title XVIII of the Social Security Act to exempt certain drugs 
 from the part D manufacturer discount program under the Medicare 
 program.

 Be it enacted by the Senate and House of Representatives of the 
United States of America in Congress assembled,

SECTION 1. SHORT TITLE.

 This Act may be cited as the ``Ensuring Access to Essential Drugs 
Act''.

SEC. 2. EXEMPTING CERTAIN DRUGS FROM THE PART D MANUFACTURER DISCOUNT 
 PROGRAM UNDER THE MEDICARE PROGRAM.

 

Section 1860D-14C

    (g)

    (2) of the Social Security Act (42 U.S.C. 
1395w-114c

    (g)

    (2) ) is amended--

    (1) in subparagraph
        (A) , by striking ``and'' at the end;

    (2) in subparagraph
        (B) , by striking the period and 
 inserting ``; and''; and

    (3) by adding at the end the following new subparagraph:
 ``
            (C) does not include an orally administered 
 drug--
 ``
            (i) for which a new drug application was 
 approved under 

section 505 of the Federal Food, 
 Drug, and Cosmetic Act; and
 ``
            (ii) that has been granted a narrow 
 exception permitting reclassification as a 
 noninnovator multiple source drug under the 
 Medicaid drug rebate program by the Centers for 
 Medicare & Medicaid Services.''.
 <all>